
Twelve years of multiples investors have paid for Rossari Biotech Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Rossari Biotech Ltd trades at a P/E of 18.77× and P/B of 2.10×.
Twelve years of audited numbers for Rossari Biotech Ltd, switchable between annual and quarterly views, consolidated or standalone.
Rossari Biotech Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,835.07 Cr and reported EPS of ₹26.91.
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,396 |
| Other Income | 9 | 12 | 5 | 7 | 4 | 22 |
| Total Income | 719 | 1,495 | 1,661 | 1,838 | 2,084 | 2,419 |
| Cost of Goods Sold (COGS) | 462 | 1,105 | 1,171 | 1,294 | 1,433 | 1,669 |
| Gross Profit | 247 | 378 | 485 | 537 | 647 | 728 |
| +Operating Expenses | 124 | 194 | 262 | 287 | 382 | 442 |
| EBITDA | 123 | 183 | 223 | 250 | 265 | 286 |
| +Non-Operating Expenses | 26 | 61 | 85 | 80 | 85 | 108 |
| Profit Before Tax (PBT) | 106 | 135 | 143 | 177 | 184 | 201 |
| +Tax Expense | 27 | 39 | 37 | 47 | 49 | 53 |
| Profit After Tax (PAT) | 80 | 98 | 107 | 131 | 136 | 149 |
| Earnings Per Share (EPS) | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 26.94 |
| Diluted Shares Outstanding (Nos.) | 5 | 6 | 6 | 6 | 6 | 6 |
| +Additional Disclosures | 1,075 | 2,467 | 2,691 | 2,954 | 3,333 | 3,889 |
| Sales Growth % | — | 109.06 | 11.66 | 10.55 | 13.64 | 15.19 |
| YoY Sales Growth % | — | 109.06 | 11.66 | 10.55 | 13.64 | 15.19 |
| Material Cost % | 61 | 65 | 65 | 67 | 62 | 67 |
| Employee Cost % | 6 | 5 | 6 | 6 | 6 | 6 |
| Other Cost % | 12 | 9 | 10 | 10 | 12 | 12 |
| OPM % | 17 | 12 | 13 | 14 | 13 | 12 |
| Tax % | 25 | 29 | 26 | 26 | 26 | 27 |
| Profit Growth % | — | 22.05 | 9.79 | 21.85 | 4.35 | 9.41 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 100 | 135 | 160 | 189 | 198 | 207 |
Disclosed business segments at Rossari Biotech with their share of revenue and profit, switchable between consolidated and standalone reporting.
Rossari Biotech discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Why someone would buy Rossari Biotech Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Rossari Biotech Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
ROE 12.20% and ROCE 15.80% indicate strong operational efficiency and profitability.
Substantial 68.2% promoter holding reflects strong insider confidence and management alignment.
Consistent quarterly sales growth of 17.60% to ₹586 crore shows market demand.
Low debt-to-equity ratio 0.18 indicates prudent financial management, reducing risk.
Attractive P/E ratio of 25.56 is lower than many industry peers.
Significant stock volatility, 52-week range ₹568-₹885, indicates considerable price risk.
Very low dividend yield of 0.08% may not appeal to income investors.
Declining FII holdings (8.51% to 2.70%) signal decreased foreign investor confidence.
Negative TTM revenue growth of -32.30% raises concerns about recent performance.
Negative TTM EPS growth of -1.64% indicates recent earnings contraction.
Trim if P/E re-rates above 24. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 33.20. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Rossari Biotech Ltd is highlighted for quick read-across.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Rossari Biotech Ltd — derived from the live tape, not yesterday's close.
Rossari Biotech Ltd last traded at ₹511.5 with an intraday range of ₹506.45–₹517.9 — live indicator, pivot and CPR signals below.
Standard pivot — most widely referenced.
| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 540.35 | +28.85 | +5.64% |
| R3 | 528.90 | +17.40 | +3.40% |
| R2 | 523.40 | +11.90 | +2.33% |
| R1 | 517.45 | +5.95 | +1.16% |
| PIVOT | 511.95 | 0.45 | 0.09% |
| CURRENT | 511.50 | — | — |
| S1 | 483.10 | -28.40 | -5.55% |
| S2 | 494.55 | -16.95 | -3.31% |
| S3 | 500.50 | -11.00 | -2.15% |
| S4 | 506.00 | -5.50 | -1.08% |
ROSSARI is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 506.45 ~ 514
Trading Inside opening range
Daily traded volume and delivery percentage for Rossari Biotech Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Rossari Biotech Ltd stood at 51.8% of traded volume, against a 20-day average of 43.5%.
Filings Rossari Biotech sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Rossari Biotech files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 107 documents below.
Sunil Chari has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Audio recording of Earnings Conference Call for Q4 FY26.
Intimation of completion of tenure of Ms. Aparna Sharma (DIN:07132341) as an Independent Director of the Company from the close of business hours of…
Rossari Biotech Limited has informed the Exchange about Investor Presentation
Rossari Biotech Limited informed the Exchange regarding Press Release dated April 27, 2026 titled " Rossari Biotech announces Q4 FY 26 results".
Every dividend, stock split and bonus issue Rossari Biotech has declared, sequenced by announce and record date.
Rossari Biotech corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
What Rossari Biotech Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Rossari Biotech Ltd operates in the Basic Materials, listed as NSE: ROSSARI, BSE: 543213.

Rossari Biotech Limited is a prominent Indian manufacturer and seller of specialty chemicals, serving both domestic and international markets. Their diverse portfolio encompasses a wide range of applications, showcasing their extensive capabilities within the chemical industry. This breadth allows them to cater to various sectors, demonstrating adaptability and a strategic focus on multiple revenue streams. The company's operational structure is built on a foundation of manufacturing and direct sales, giving them direct control over the production process and market access.
A significant portion of Rossari's business is dedicated to the production and distribution of chemicals for the soap and detergent industry. This is a substantial market segment, and Rossari's presence indicates their competitiveness and ability to meet the demands of this sector. Beyond detergents, they supply chemicals for inks, paints, coatings, ceramics, tiles, pulp and paper production, and cement manufacturing, highlighting the versatility of their chemical offerings and their significant contribution to several essential industrial processes.
Rossari further distinguishes itself through its specialized textile chemical offerings. This segment showcases a deep understanding of the textile industry's diverse needs. They provide chemicals tailored for various fabric types including cotton, polyester, acrylic, wool, silk, and nylon, demonstrating expertise in diverse textile processing techniques. Their commitment extends to functional finishes, denim processing, printing, and environmentally sustainable solutions, reflecting a focus on innovation and meeting contemporary industry demands.
In addition to its industrial chemical production, Rossari has expanded into consumer goods with its line of pet grooming products. These products, marketed under the brands Lozalo, Hunger Fills, and Sniffy, include shampoos, powders, deodorants, sprays, creams, and floor washing liquids. This diversification demonstrates a strategy to broaden their market reach and tap into consumer demand for pet care products. The company also produces poultry nutrition products, including vitamin-mineral formulations, enzyme blends, and herbal supplements, indicating expansion into the agricultural sector and the growing market for animal nutrition.
Founded in 1997 and headquartered in Mumbai, Rossari Biotech has evolved significantly since its inception as Rossari Labtech. The company's continuous growth and diversification illustrate a commitment to innovation, market expansion, and a strong understanding of various industry needs. Their success hinges on their ability to adapt to market trends and deliver high-quality chemical solutions for various sectors, ranging from industrial manufacturing to consumer products.
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
The current share price of Rossari Biotech Ltd (ROSSARI) is ₹511.5. Today, the stock has gained by ₹7.55 (1.50%), trading in a range of ₹506.45 to ₹517.9. The stock opened at ₹510 with a trading volume of 50,507 shares.
Rossari Biotech Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,835.07 crores, P/E ratio of 18.77, ROE of 11.85%, and ROCE of 15.80%. The dividend yield stands at 0.10%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Rossari Biotech Ltd (ROSSARI) is ₹766, while the 52-week low is ₹375. Currently trading at ₹511.5, the stock is 34.9% away from its 52-week low and 33.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Rossari Biotech Ltd stock at ₹511.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 18.77 and P/B ratio of 2.10. Today's performance shows a gain of 1.50%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Rossari Biotech Ltd offers a dividend yield of 0.10%, which means for every ₹100 invested at the current price of ₹511.5, you can expect to receive approximately ₹0.10 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Rossari Biotech Ltd's key financial metrics include: P/E Ratio: 18.77, P/B Ratio: 2.10, ROE: 11.85%, ROCE: 15.80%, Dividend Yield: 0.10%, EPS: ₹26.91, Book Value: ₹240.76, and Debt-to-Equity: 32.70. The company's market cap stands at ₹2,835.07 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Rossari Biotech Ltd stock opened at ₹510 and is currently trading at ₹511.5, showing a gain of ₹7.55 (1.50%). The intraday high is ₹517.9 and low is ₹506.45. The trading volume stands at 50,507 shares, indicating moderate market participation today.
Rossari Biotech Ltd has a Price-to-Earnings (P/E) ratio of 18.77, which means investors are willing to pay ₹18.77 for every ₹1 of earnings. With an EPS of ₹26.91, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Rossari Biotech Ltd (ROSSARI) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Peers, sector trends, screeners and strategy playbooks contextual to this stock.